• +1-646-491-9876
    • +91-20-67278686

    Search

    Idiopathic Thrombocytopenic Purpura-Pipeline Review H2 2017

    Idiopathic Thrombocytopenic Purpura-Pipeline Review H2 2017

    • Report Code ID: RW00011022676
    • Category Life Sciences
    • No. of Pages 120
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H2 2017, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline landscape.

    Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 5, 8, 3, 2 and 7 respectively.

    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).
    -The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 3
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Overview 6
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Products under Development by Companies 11
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics Assessment 14
    Assessment by Target 14
    Assessment by Mechanism of Action 16
    Assessment by Route of Administration 18
    Assessment by Molecule Type 20
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Companies Involved in Therapeutics Development 22
    3SBio Inc 22
    Amgen Inc 22
    arGEN-X BV 23
    Biogen Inc 23
    Boehringer Ingelheim GmbH 24
    Bristol-Myers Squibb Company 24
    CSL Ltd 25
    Dova Pharmaceuticals Inc 25
    Enzene Biosciences Ltd 26
    Genosco Inc 26
    GlaxoSmithKline Plc 27
    Hansa Medical AB 27
    Immunomedics Inc 28
    Intas Pharmaceuticals Ltd 28
    Jiangsu Hengrui Medicine Co Ltd 29
    Momenta Pharmaceuticals Inc 30
    Novartis AG 31
    Pfizer Inc 32
    Pharmagenesis Inc 32
    Protalex Inc 33
    Rigel Pharmaceuticals Inc 33
    UCB SA 34
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Drug Profiles 35
    avatrombopag-Drug Profile 35
    belimumab-Drug Profile 38
    BI-655064-Drug Profile 46
    efgartigimod alfa-Drug Profile 48
    eltrombopag olamine-Drug Profile 51
    eltrombopag olamine-Drug Profile 58
    fostamatinib disodium-Drug Profile 59
    GL-2045-Drug Profile 65
    Hetrombopag Olamine-Drug Profile 67
    KLM-465-Drug Profile 68
    letolizumab-Drug Profile 70
    M-230-Drug Profile 71
    M-254-Drug Profile 72
    M-281-Drug Profile 73
    PBF-1650-Drug Profile 74
    PHN-013-Drug Profile 75
    PRTX-100-Drug Profile 76
    Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases-Drug Profile 83
    rituximab-Drug Profile 84
    romiplostim-Drug Profile 91
    romiplostim biosimilar-Drug Profile 95
    romiplostim biosimilar-Drug Profile 96
    rozanolixizumab-Drug Profile 97
    SKIO-703-Drug Profile 98
    thrombopoietin-Drug Profile 100
    veltuzumab-Drug Profile 101
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects 105
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products 106
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Product Development Milestones 107
    Featured News & Press Releases 107
    Appendix 117
    Methodology 117
    Coverage 117
    Secondary Research 117
    Primary Research 117
    Expert Panel Validation 117
    Contact Us 117
    Disclaimer 118

    List of Tables
    Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by 3SBio Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Amgen Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by arGEN-X BV, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Biogen Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Boehringer Ingelheim GmbH, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Bristol-Myers Squibb Company, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by CSL Ltd, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Dova Pharmaceuticals Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Enzene Biosciences Ltd, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Genosco Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by GlaxoSmithKline Plc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Hansa Medical AB, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Immunomedics Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Intas Pharmaceuticals Ltd, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Momenta Pharmaceuticals Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Novartis AG, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Pfizer Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Pharmagenesis Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Protalex Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Rigel Pharmaceuticals Inc, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by UCB SA, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects, H2 2017
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    3SBio Inc
    Amgen Inc
    arGEN-X BV
    Biogen Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    CSL Ltd
    Dova Pharmaceuticals Inc
    Enzene Biosciences Ltd
    Genosco Inc
    GlaxoSmithKline Plc
    Hansa Medical AB
    Immunomedics Inc
    Intas Pharmaceuticals Ltd
    Jiangsu Hengrui Medicine Co Ltd
    Momenta Pharmaceuticals Inc
    Novartis AG
    Pfizer Inc
    Pharmagenesis Inc
    Protalex Inc
    Rigel Pharmaceuticals Inc
    UCB SA

    Request for Sample

    Report Url http://www.reportsweb.com//idiopathic-thrombocytopenic-purpura-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//idiopathic-thrombocytopenic-purpura-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//idiopathic-thrombocytopenic-purpura-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments